CNS Pharmaceuticals, Inc. short interest in 2021
In 2021, CNS Pharmaceuticals, Inc.'s disclosed short interest ran from 0.85% of shares outstanding on 15 Jan 2021 to 0.92% on 31 Dec 2021, a change of +0.07 percentage points. The year's high was 2.39% on 15 Jul 2021 and its low 0.40% on 29 Jan 2021, averaging 1.37% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.47 days on 13 Aug 2021. Full history: CNS Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 0.85% (15 Jan 2021)
- End of year
- 0.92% (31 Dec 2021)
- Change
- +0.07 pp
- High
- 2.39% (15 Jul 2021)
- Low
- 0.40% (29 Jan 2021)
- Average
- 1.37%
- Highest days to cover
- 4.47 (13 Aug 2021)
- SEC filings marked
- 5
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 0.85% | 1.00 | |
| 29 Jan 2021 | 0.40% | 1.00 | |
| 12 Feb 2021 | 2.06% | 1.00 | 10-K filed |
| 26 Feb 2021 | 2.07% | 1.00 | |
| 15 Mar 2021 | 2.04% | 1.67 | |
| 31 Mar 2021 | 1.50% | 1.00 | |
| 15 Apr 2021 | 1.24% | 2.45 | |
| 30 Apr 2021 | 1.19% | 1.75 | |
| 14 May 2021 | 1.32% | 2.04 | 10-Q filed |
| 28 May 2021 | 1.15% | 4.01 | |
| 15 Jun 2021 | 1.17% | 2.23 | |
| 30 Jun 2021 | 1.52% | 1.00 | |
| 15 Jul 2021 | 2.39% | 1.03 | |
| 30 Jul 2021 | 1.72% | 2.90 | |
| 13 Aug 2021 | 1.53% | 4.47 | 10-Q filed, results (8-K) |
| 31 Aug 2021 | 1.53% | 2.37 | |
| 15 Sep 2021 | 1.63% | 4.02 | |
| 30 Sep 2021 | 1.36% | 1.86 | |
| 15 Oct 2021 | 1.32% | 3.59 | |
| 29 Oct 2021 | 1.18% | 3.07 | |
| 15 Nov 2021 | 0.93% | 1.37 | 10-Q filed |
| 30 Nov 2021 | 1.08% | 1.00 | |
| 15 Dec 2021 | 0.85% | 1.42 | |
| 31 Dec 2021 | 0.92% | 1.09 |
See also: CNS Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.